Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (AldaraR)

Didona, Biagio; Benucci, Roberto; Amerio, Paolo; Canzona, Flora; Rienzo, O.; Cavalieri, R.

doi:10.1111/j.1365-2133.2004.05993.x

Cited by 43 publications

(27 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both patients had a CR, with no recurrence during the 8-month follow-up. 63 In another report, imiquimod was used 3 times weekly on a patient with cALCL, and CR was achieved. 64 …”

Section: Imiquimodmentioning

confidence: 98%

Practical Management of CD30+ Lymphoproliferative Disorders

Hughey

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Primary cutaneous CD30⁺ lymphoproliferative disorders (LPDs) account for approximately 25% of cutaneous lymphomas. Although these LPDs are clinically heterogeneous, they can be indistinguishable histologically. Lymphomatoid papulosis rarely requires systemic treatment; however, multifocal primary cutaneous anaplastic large cell cutaneous lymphoma and large cell transformation of mycosis fungoides are typically treated systemically. As CD30⁺ LPDs are rare, there is little published evidence to support a specific treatment algorithm. Most studies are case reports, small case series, or retrospective reviews. This article discusses various treatment choices for each of the CD30⁺ disorders and offers practical pearls to aid in choosing an appropriate regimen.

show abstract

“…Both patients had a CR, with no recurrence during the 8-month follow-up. 63 In another report, imiquimod was used 3 times weekly on a patient with cALCL, and CR was achieved. 64 …”

Section: Imiquimodmentioning

confidence: 98%

Practical Management of CD30+ Lymphoproliferative Disorders

Hughey

2015

Dermatologic Clinics

View full text Add to dashboard Cite

show abstract

“…Topical imiquimod has also been used in a variety of different skin disorders including nodular and superficial BCC (29), in situ and invasive SCC (30)(31), lentigo maligna (32), lentigo maligna melanoma (33), keratoacanthomas (34), primary cutaneous CD30 positive anaplastic large cell lymphoma (35), mycosis fungoides (36), extramammary Paget's disease (37), cutaneous melanoma metastases (38), cutaneous warts and molluscum contagiosum (39), stucco keratosis (40), cutaneous leishmaniasis (41) and keloids (42).…”

Section: Imiquimod: a Promising Topical Immunostimulatory Agent For Dmentioning

confidence: 99%

Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients

Trakatelli

Katsanos

Ulrich

et al. 2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

The potent systemic immunosuppression therapy necessary to sustain a life-saving solid organ transplant is associated with an increased incidence of various infections including human papillomavirus infection and skin cancers in organ transplant recipients. Imiquimod, a topical agent that functions through local induction of a specific anti-viral or anti-tumor immune response, appears to be a promising therapeutic option that could potentially counteract in situ the effects of systemic immunosupression in this vulnerable group. Up-to-date studies using this local immune-response modifier in transplanted patients have yielded reassuring and encouraging results regarding its safety and efficacy in this population. However, in order to establish the use of imiquimod as a standard treatment option for organ transplant recipients, additional research and clinical trials are required.The past decades have seen unprecedented progress in the development of solid organ transplantation as a therapeutic choice for endstage organ disease. Organ Transplant Recipients (OTR) live longer, have a good quality of life and represent a rapidly growing population of people with specific medical needs. As the number of solid organ transplants continues to rise, so too does the number of various infections including human papillomavirus (HPV) infections and skin cancers in OTR. Consequently, physicians will be called upon to manage these diseases in the sensitive OTR population and to develop novel therapeutic and preventive strategies to better deal with them.The clinical efficacy of imiquimod 5% cream (a topical therapy approved for genital warts, actinic keratoses and superficial basal cell carcinoma) stems from stimulation ofinnate and cell-mediated immune responses, resulting in antiviral, antiproliferative and antitumor activity. Because of these properties, imiquimod and other members of this family of immune response modifiers are potential agents for treatment of conditions where the immune system can affect the regression of the disease (1). In light of the role of systemic immunosupression in the development of cutaneous infections and neoplasms in OTR, the use of imiquimod to locally stimulate immune responses against cancerous, pre-cancerous

show abstract

“…These data suggest that imidazoquinolines, already used as topic in humans, 5 could be used as complementary chemotherapy for CLL clearance, as reported in lymphoma. 6,7 TLR9 is a natural receptor for CpG of bacterial origin. Several synthetic oligonucleotides with CpG motifs have been reported to be efficient activators of cells displaying mRNA expression of TLR9.…”

Section: This Study Reports That B-chronic Lymphocytic Leukemia (B-mentioning

confidence: 99%

Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells

Grandjenette¹,

Kennel²,

Fauré³

et al. 2007

Haematologica

View full text Add to dashboard Cite

Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (AldaraR)

Cited by 43 publications

References 13 publications

Practical Management of CD30+ Lymphoproliferative Disorders

Practical Management of CD30+ Lymphoproliferative Disorders

Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients

Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells

Contact Info

Product

Resources

About